Trial reportThe Journal of allergy and clinical immunology2020
Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE.
Trial report in The Journal of allergy and clinical immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.
- Precision Medicine in Plant Food Allergy: a Systematic Review of Biomarkers Under a Clinical Approach.Clinical reviews in allergy & immunology · 2026Pooled it
- Baseline epitope-specific IgE profiles are predictive of sustained unresponsiveness or high threshold 1-year post oral immunotherapy in the POISED trial.The Journal of allergy and clinical immunology · 2025Trial
- Peanut-Specific IgG4 and IgA in Saliva Are Modulated by Peanut Oral Immunotherapy.The journal of allergy and clinical immunology. In practice · 2022Trial
- CD8Nature communications · 2022Trial
- Kinetics of basophil hyporesponsiveness during short-course peanut oral immunotherapy.The Journal of allergy and clinical immunology · 2022Trial
- Maximum Dose Food Challenges Reveal Transient Sustained Unresponsiveness in Peanut Oral Immunotherapy (POIMD Study).The journal of allergy and clinical immunology. In practice · 2022Trial
- Safety and efficiency of peanut oral immunotherapy in preschool children with slow up-dosing and low maintenance dosing: a randomised controlled trial.The Lancet regional health. Europe · 2026Article
- Peanut Oral Immunotherapy in Children: An Italian Single-Center Retrospective Cohort Study.Nutrients · 2026Article
- AAV Gene Therapy for MPS IVA with Induction of Immune Tolerance via Oral Administration of Epitope Peptides of N-Acetylgalactosamine-6-sulfate Sulfatase.International journal of molecular sciences · 2026Article
- Modulating the Allergen-Specific Immune Response to Achieve Remission of Food Allergy Through Oral Immunotherapy.Advances in experimental medicine and biology · 2026Review
- Innovative diagnostic techniques and their clinical implications in food allergy: current clinical practice and future perspectives.Frontiers in allergy · 2026Review
- Gut mucosal immune responses - Implications for celiac disease and food allergy.Seminars in immunology · 2025Review
- A hand-operated microfluidic sample preparation-to-analysis workflow for simplifying the basophil activation test.Lab on a chip · 2025Article
- Biomarker-driven drug development for allergic diseases and asthma: An FDA public workshop.The Journal of allergy and clinical immunology · 2025Article
- Elucidation of Desensitization Mechanisms Induced by Oral Immunotherapy in a Rat Model of Ovalbumin Allergy.Foods (Basel, Switzerland) · 2025Article
- Emerging diagnostic and therapeutic opportunities in food allergy.Frontiers in immunology · 2025Review
- Omalizumab Implementation in Practice: Lessons Learned From the OUtMATCH Study.The journal of allergy and clinical immunology. In practice · 2024Article
- Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways.Immunological reviews · 2024Review
- Can artificial intelligence (AI) replace oral food challenge?The Journal of allergy and clinical immunology · 2024Article
- Combining avidin with CD63 improves basophil activation test accuracy in classifying peanut allergy.Allergy · 2024Article
Corrections and comments
- Erratum issuedCorrigendum.2020
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundOral immunotherapy (OIT) can successfully desensitize many peanut-allergic subjects, but clinical tolerance diminishes over time on discontinuation, or low-dose maintenance, of peanut. Therefore, to improve the efficacy and sustainability of such therapy, we sought to identify biomarkers and clinical tools that can predict therapeutic outcomes and monitor treatment responses.
objectiveWe evaluated whether basophil activation in whole blood, and plasma levels of peanut-specific immunoglobulins, are useful biomarkers for peanut OIT.
methodsWe longitudinally measured, before, during, and after OIT, basophil activation in whole blood ex vivo in response to peanut stimulation, and peanut-specific IgE (sIgE) and peanut-specific IgG
resultsPeanut OIT significantly decreased basophil activation, peanut sIgE, Ara h 1, Ara h 2, and Ara h 3 IgE levels, and sIgE/total IgE, but increased sIgG
conclusionsAssessments of peanut-induced basophil activation and peanut-specific immunoglobulins can help to predict treatment outcomes, and to differentiate transient desensitization versus sustained unresponsiveness after OIT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.